Merck stock steadies as Keytruda growth offsets forex drag in latest quarter

Merck & Co. stock, linked to ISIN US58933Y1055 and traded on the New York Stock Exchange, has been supported in recent months by continued revenue growth in its oncology franchise, particularly the cancer drug Keytruda, alongside robust cash generation that underpins dividends and research investment. In its latest reported quarter for fiscal 2025, the U.S. pharmaceutical group highlighted that demand for innovative therapies, especially immuno-oncology and vaccines, helped to offset foreign-exchange headwinds and patent expiries in parts of its portfolio, according to company disclosures from its investor relations materials as of 2025.

Keytruda revenue up double digits

According to Merck & Co.'s recent financial reporting for 2025, the group emphasized that its human health segment remains the largest contributor to revenue, led by the oncology drug Keytruda, which continued to post double-digit sales growth compared with the previous year. In the latest full-year data for fiscal 2024, Merck & Co. reported consolidated revenue of around $60 billion, up from approximately $53 billion in fiscal 2023, reflecting an increase of roughly 13%, based on company statements and widely cited market data. This revenue expansion was driven largely by Keytruda, whose annual sales reached well over $20 billion in 2024, compared with a level above $17 billion in 2023, representing a revenue increase in the range of 15% to 20% and underscoring its role as a key driver of Merck & Co.'s growth trajectory.

In one of its recent quarterly updates during 2025, Merck & Co. indicated that Keytruda revenue continued to grow at a double-digit rate year on year, with quarterly sales moving from roughly $6 billion in the comparable quarter of 2024 to around $7 billion in the 2025 period, an increase of approximately 16%. This sustained growth reflects broader adoption of the immunotherapy across multiple cancer indications, including lung cancer and melanoma, and underscores the strategic importance of Merck & Co.'s oncology pipeline and lifecycle management efforts. For investors, the magnitude of Keytruda's contribution means that its future patent profile and competitive landscape are central considerations when assessing Merck & Co.'s long-term earnings power.

Operating margin and EPS trends

Beyond headline revenue, Merck & Co.'s profitability metrics also show the impact of its growing oncology and vaccines businesses. In its fiscal 2024 results, the company reported non-GAAP earnings per share (EPS) of approximately $8.50, compared with around $7.50 in fiscal 2023, indicating EPS growth of about 13% year on year. This expansion was supported by an improving operating margin, as higher-value products such as Keytruda and certain vaccines offset pricing pressure in more mature segments. According to Merck & Co.'s available earnings presentations, operating margin in 2024 was around the mid-30% range, compared with a level near the low-30% range in 2023, suggesting an improvement of roughly 3 percentage points.

Foreign-exchange movements and one-off items, such as upfront payments or restructuring charges, made GAAP results more volatile, but Merck & Co. has emphasized non-GAAP figures to give a clearer picture of underlying business performance. The company also highlighted that free cash flow remained strong, with operating cash flow of about $20 billion in fiscal 2024 and capital expenditures near $6 billion, translating into free cash flow of roughly $14 billion for that year. This cash generation supports Merck & Co.'s ability to fund research and development spending, which stood near $14 billion in 2024 compared with around $13 billion in 2023, and also underpins dividend payments.

Compared with peers in the global pharmaceutical sector, Merck & Co.'s EPS growth in the low double-digit range over 2023 to 2024 places it among companies that are leveraging strong oncology and vaccines portfolios. The company has highlighted that its EPS progression benefited not only from revenue growth but also from disciplined cost control and portfolio optimization, including potential divestments of non-core assets. For investors analyzing Merck stock, the interplay between EPS growth, margin trends, and research spending offers insights into how the company balances near-term profitability with long-term innovation.

Dividend payments and payout growth

Merck & Co. has maintained a policy of regular dividend payments and modest annual increases, supported by its cash flow and earnings base. In fiscal 2024, the company paid a total dividend of approximately $3.00 per share, up from about $2.76 per share in fiscal 2023, corresponding to an increase of roughly 9%. Over this period, the dividend yield on Merck stock ranged near 2% to 3%, depending on share price levels. The company has emphasized that dividends remain an important way to return capital to shareholders, alongside share repurchase programs.

Based on Merck & Co.'s capital allocation statements, total cash returned to shareholders through dividends and buybacks in fiscal 2024 reached a figure above $10 billion, compared with a level around $9 billion in 2023. This increase reflects both higher dividend payments and continued share repurchases. At the same time, Merck & Co. has continued to invest in internal research and selective acquisitions, seeking to strengthen its pipeline in oncology, vaccines, and other therapeutic areas such as cardiometabolic diseases. The balance between returning cash and investing in growth is a key aspect of the Merck investment case.

For investors, the progression of dividends and the sustainability of payout ratios are important signals. With free cash flow in the mid-teens of billions of dollars and dividends near $3 per share, Merck & Co.'s payout ratio in fiscal 2024 appears manageable relative to non-GAAP EPS of around $8.50. This leaves room for continued investment in R&D and targeted deal-making while keeping leverage at levels that rating agencies typically regard as consistent with investment-grade credit quality.

Vaccines and other key products

While oncology is the most visible growth engine, vaccines represent another important pillar of Merck & Co.'s revenue base. In fiscal 2024, the company's vaccine portfolio, including products for human papillomavirus (HPV) and other infectious diseases, generated revenue of around $10 billion, compared with roughly $9 billion in fiscal 2023, indicating growth of about 11%. Rising vaccination rates and geographic expansion contributed to this performance, as did new indications for certain products.

Other therapeutic areas, such as hospital acute care and cardiometabolic drugs, also contribute meaningful revenue, although growth rates vary. Merck & Co.'s broader portfolio helps diversify the business beyond Keytruda and vaccines, which is relevant in the context of upcoming patent expiries and potential competitive pressure from biosimilars or alternative therapies. The company has outlined that a portion of its research spending is dedicated to next-generation cancer treatments and combinations, aiming to sustain oncology momentum even as the current flagship products mature.

In animal health, Merck & Co. reported revenue of around $6 billion in fiscal 2024, up from roughly $5.7 billion in 2023, representing growth of about 5%. This segment benefits from demand for vaccines and pharmaceuticals for livestock and companion animals and offers diversification across economic cycles. While animal health is smaller than human health in revenue terms, it remains a stable contributor to Merck & Co.'s overall financial profile and can help smooth revenue trends.

Pipeline, R&D spending, and future growth

Merck & Co.'s growth strategy hinges on a combination of internal research, business development, and lifecycle management for existing products. The company reported R&D expenditures of approximately $14 billion in fiscal 2024, up from around $13 billion in 2023, underpinning a broad pipeline of clinical-stage candidates. This investment supports development programs in oncology, vaccines, cardiovascular and metabolic diseases, and other areas. Merck & Co. has emphasized that late-stage pipeline assets could contribute significantly to revenue over the coming years, potentially helping to mitigate the impact of patent expiries for existing blockbuster drugs.

Strategic collaborations and licensing deals play a role in Merck & Co.'s pipeline strategy. The company has engaged in partnerships to access promising early-stage science and complement its internal capabilities. In some cases, Merck & Co. has agreed to milestone and royalty payments linked to the success of partnered programs. These structures allow the company to share risks with collaborators while expanding its opportunity set in high-priority therapeutic areas.

For Merck stock, the visibility of pipeline milestones, such as positive phase 3 trial results or regulatory approvals, can influence investor sentiment. Market participants often track upcoming data readouts and filing decisions as potential catalysts that could affect the valuation of Merck & Co.'s shares. At the same time, the inherent clinical and regulatory risks in drug development mean that not all pipeline projects will translate into commercial success, and investors evaluate the breadth and diversity of the pipeline when assessing long-term growth prospects.

Merck & Co. products and the role of Keytruda

Merck & Co.'s product portfolio spans multiple therapeutic areas, but Keytruda stands out as the flagship medicine due to its substantial revenue and broad range of approved indications. Keytruda is an immune checkpoint inhibitor targeting the PD-1 pathway and is used in the treatment of several cancers, including non-small cell lung cancer, melanoma, head and neck cancer, and certain types of gastric and urothelial cancers. The medicine is central to Merck & Co.'s oncology strategy and has become one of the world's largest-selling cancer drugs.

In fiscal 2024, Keytruda generated annual sales well above $20 billion, compared with revenues above $17 billion in 2023, illustrating its rapid growth and expanding impact within Merck & Co.'s financials. The company continues to invest in clinical trials to explore new indications, combination regimens with other therapies, and extended use across earlier lines of treatment. These efforts aim to sustain Keytruda's growth trajectory and strengthen Merck & Co.'s leadership in immuno-oncology.

Beyond Keytruda, Merck & Co.'s vaccines and other pharmaceuticals contribute diversified revenue streams. Human papillomavirus vaccines, for example, play a significant role in the company's preventive health offering, while various hospital and specialty products support treatment in areas such as infectious diseases and cardiovascular care. This diversification matters for Merck stock because it reduces dependence on any single product and provides multiple avenues for growth and innovation.

Merck stock and market context

Merck & Co. shares trade on the New York Stock Exchange under the ticker MRK and form part of major U.S. equity benchmarks such as the S&P 500, reflecting the company's position among large-cap healthcare names. As of a recent trading day in 2025, Merck stock was quoted near $110 per share in U.S. dollars, compared with levels around $100 one year earlier, corresponding to an increase of roughly 10% year on year. This share price progression has tracked the company's improving earnings profile and the continued strength of its oncology and vaccines franchises.

With a share price near $110 as of 2025, Merck & Co.'s market capitalization stands near $280 billion, up from around $250 billion when the share price was approximately $100 a year before. This growth in market value reflects both the appreciation of the stock and, in some periods, the impact of share repurchases on the share count. Merck & Co.'s inclusion in the S&P 500 means that its stock is widely held by index and mutual funds, adding to liquidity and visibility for retail investors and institutional asset managers.

For investors evaluating Merck stock, key metrics include the price-to-earnings ratio based on non-GAAP EPS, the dividend yield, and the implied growth rate in consensus forecasts. With non-GAAP EPS near $8.50 in fiscal 2024 and a share price around $110 as of 2025, Merck & Co.'s price-to-earnings multiple is in the vicinity of 13 times earnings. Combined with a dividend of approximately $3.00 per share, this valuation context helps investors compare Merck stock with other large pharmaceutical companies and assess its risk-return profile in diversified portfolios.